Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer
Background Tumor immune escape and angiogenesis contribute to tumor progression, and gangliosides and activation of signal transducer and activator of transcription (STAT)-3 are implicated in these processes. As both are considered as novel therapeutic targets, we assessed the possible association o...
Uložené v:
| Vydané v: | BMC cancer Ročník 9; číslo 1; s. 180 |
|---|---|
| Hlavní autori: | , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
London
BioMed Central
11.06.2009
BioMed Central Ltd BMC |
| Predmet: | |
| ISSN: | 1471-2407, 1471-2407 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Background
Tumor immune escape and angiogenesis contribute to tumor progression, and gangliosides and activation of signal transducer and activator of transcription (STAT)-3 are implicated in these processes. As both are considered as novel therapeutic targets, we assessed the possible association of ganglioside GM3 expression and STAT3 activation with suppression of dendritic cell (DC) activation and angiogenesis in non-small cell lung cancer (NSCLC).
Methods
Immunohistochemistry was performed on a tissue array to determine
N
-glycolyl GM3 (GM3) and phosphorylated STAT3 (pSTAT3) expression in 176 primary NSCLC resections. Median values of GM3 and pSTAT3 expression were used as cut off. Microvessel density (MVD) was determined by CD34 staining and morphology. CD1a and CD83 were used to determine infiltrating immature and mature dendritic cells, respectively.
Results
94% and 71% of the NSCLC samples expressed GM3 and nuclear pSTAT3, respectively. Median overall survival was 40.0 months. Both low GM3 expression and high pSTAT3 expression were associated with a worse survival, which reached near significance for GM3 (
P
= 0.08). Microvessel density (MVD), determined by CD34 staining and morphology, was lower in NSCLC samples with high GM3 expression. CD1a
+
cells (immature DCs) were more frequent in NSCLC tissues as compared to peritumoral lung tissue, while CD83
+
cells (mature DCs) were more frequent in peritumoral lung tissue. CD83
+
DCs were less frequent in NSCLC tissues with high GM3 expression.
Conclusion
GM3 and pSTAT3 are widely expressed in NSCLC. Based on CD83 expression, GM3, but not pSTAT3, appeared to be involved in tumor-induced DC suppression. pSTAT3 expression was not associated with MVD, while GM3 might play an anti-angiogenic role. |
|---|---|
| AbstractList | Background Tumor immune escape and angiogenesis contribute to tumor progression, and gangliosides and activation of signal transducer and activator of transcription (STAT)-3 are implicated in these processes. As both are considered as novel therapeutic targets, we assessed the possible association of ganglioside GM3 expression and STAT3 activation with suppression of dendritic cell (DC) activation and angiogenesis in non-small cell lung cancer (NSCLC). Methods Immunohistochemistry was performed on a tissue array to determine N-glycolyl GM3 (GM3) and phosphorylated STAT3 (pSTAT3) expression in 176 primary NSCLC resections. Median values of GM3 and pSTAT3 expression were used as cut off. Microvessel density (MVD) was determined by CD34 staining and morphology. CD1a and CD83 were used to determine infiltrating immature and mature dendritic cells, respectively. Results 94% and 71% of the NSCLC samples expressed GM3 and nuclear pSTAT3, respectively. Median overall survival was 40.0 months. Both low GM3 expression and high pSTAT3 expression were associated with a worse survival, which reached near significance for GM3 (P = 0.08). Microvessel density (MVD), determined by CD34 staining and morphology, was lower in NSCLC samples with high GM3 expression. CD1a.sup.+ .sup.cells (immature DCs) were more frequent in NSCLC tissues as compared to peritumoral lung tissue, while CD83.sup.+ .sup.cells (mature DCs) were more frequent in peritumoral lung tissue. CD83.sup.+ .sup.DCs were less frequent in NSCLC tissues with high GM3 expression. Conclusion GM3 and pSTAT3 are widely expressed in NSCLC. Based on CD83 expression, GM3, but not pSTAT3, appeared to be involved in tumor-induced DC suppression. pSTAT3 expression was not associated with MVD, while GM3 might play an anti-angiogenic role. Tumor immune escape and angiogenesis contribute to tumor progression, and gangliosides and activation of signal transducer and activator of transcription (STAT)-3 are implicated in these processes. As both are considered as novel therapeutic targets, we assessed the possible association of ganglioside GM3 expression and STAT3 activation with suppression of dendritic cell (DC) activation and angiogenesis in non-small cell lung cancer (NSCLC). Immunohistochemistry was performed on a tissue array to determine N-glycolyl GM3 (GM3) and phosphorylated STAT3 (pSTAT3) expression in 176 primary NSCLC resections. Median values of GM3 and pSTAT3 expression were used as cut off. Microvessel density (MVD) was determined by CD34 staining and morphology. CD1a and CD83 were used to determine infiltrating immature and mature dendritic cells, respectively. 94% and 71% of the NSCLC samples expressed GM3 and nuclear pSTAT3, respectively. Median overall survival was 40.0 months. Both low GM3 expression and high pSTAT3 expression were associated with a worse survival, which reached near significance for GM3 (P = 0.08). Microvessel density (MVD), determined by CD34 staining and morphology, was lower in NSCLC samples with high GM3 expression. CD1a.sup.+ .sup.cells (immature DCs) were more frequent in NSCLC tissues as compared to peritumoral lung tissue, while CD83.sup.+ .sup.cells (mature DCs) were more frequent in peritumoral lung tissue. CD83.sup.+ .sup.DCs were less frequent in NSCLC tissues with high GM3 expression. GM3 and pSTAT3 are widely expressed in NSCLC. Based on CD83 expression, GM3, but not pSTAT3, appeared to be involved in tumor-induced DC suppression. pSTAT3 expression was not associated with MVD, while GM3 might play an anti-angiogenic role. Tumor immune escape and angiogenesis contribute to tumor progression, and gangliosides and activation of signal transducer and activator of transcription (STAT)-3 are implicated in these processes. As both are considered as novel therapeutic targets, we assessed the possible association of ganglioside GM3 expression and STAT3 activation with suppression of dendritic cell (DC) activation and angiogenesis in non-small cell lung cancer (NSCLC).BACKGROUNDTumor immune escape and angiogenesis contribute to tumor progression, and gangliosides and activation of signal transducer and activator of transcription (STAT)-3 are implicated in these processes. As both are considered as novel therapeutic targets, we assessed the possible association of ganglioside GM3 expression and STAT3 activation with suppression of dendritic cell (DC) activation and angiogenesis in non-small cell lung cancer (NSCLC).Immunohistochemistry was performed on a tissue array to determine N-glycolyl GM3 (GM3) and phosphorylated STAT3 (pSTAT3) expression in 176 primary NSCLC resections. Median values of GM3 and pSTAT3 expression were used as cut off. Microvessel density (MVD) was determined by CD34 staining and morphology. CD1a and CD83 were used to determine infiltrating immature and mature dendritic cells, respectively.METHODSImmunohistochemistry was performed on a tissue array to determine N-glycolyl GM3 (GM3) and phosphorylated STAT3 (pSTAT3) expression in 176 primary NSCLC resections. Median values of GM3 and pSTAT3 expression were used as cut off. Microvessel density (MVD) was determined by CD34 staining and morphology. CD1a and CD83 were used to determine infiltrating immature and mature dendritic cells, respectively.94% and 71% of the NSCLC samples expressed GM3 and nuclear pSTAT3, respectively. Median overall survival was 40.0 months. Both low GM3 expression and high pSTAT3 expression were associated with a worse survival, which reached near significance for GM3 (P = 0.08). Microvessel density (MVD), determined by CD34 staining and morphology, was lower in NSCLC samples with high GM3 expression. CD1a+ cells (immature DCs) were more frequent in NSCLC tissues as compared to peritumoral lung tissue, while CD83+ cells (mature DCs) were more frequent in peritumoral lung tissue. CD83+ DCs were less frequent in NSCLC tissues with high GM3 expression.RESULTS94% and 71% of the NSCLC samples expressed GM3 and nuclear pSTAT3, respectively. Median overall survival was 40.0 months. Both low GM3 expression and high pSTAT3 expression were associated with a worse survival, which reached near significance for GM3 (P = 0.08). Microvessel density (MVD), determined by CD34 staining and morphology, was lower in NSCLC samples with high GM3 expression. CD1a+ cells (immature DCs) were more frequent in NSCLC tissues as compared to peritumoral lung tissue, while CD83+ cells (mature DCs) were more frequent in peritumoral lung tissue. CD83+ DCs were less frequent in NSCLC tissues with high GM3 expression.GM3 and pSTAT3 are widely expressed in NSCLC. Based on CD83 expression, GM3, but not pSTAT3, appeared to be involved in tumor-induced DC suppression. pSTAT3 expression was not associated with MVD, while GM3 might play an anti-angiogenic role.CONCLUSIONGM3 and pSTAT3 are widely expressed in NSCLC. Based on CD83 expression, GM3, but not pSTAT3, appeared to be involved in tumor-induced DC suppression. pSTAT3 expression was not associated with MVD, while GM3 might play an anti-angiogenic role. Abstract Background Tumor immune escape and angiogenesis contribute to tumor progression, and gangliosides and activation of signal transducer and activator of transcription (STAT)-3 are implicated in these processes. As both are considered as novel therapeutic targets, we assessed the possible association of ganglioside GM3 expression and STAT3 activation with suppression of dendritic cell (DC) activation and angiogenesis in non-small cell lung cancer (NSCLC). Methods Immunohistochemistry was performed on a tissue array to determine N-glycolyl GM3 (GM3) and phosphorylated STAT3 (pSTAT3) expression in 176 primary NSCLC resections. Median values of GM3 and pSTAT3 expression were used as cut off. Microvessel density (MVD) was determined by CD34 staining and morphology. CD1a and CD83 were used to determine infiltrating immature and mature dendritic cells, respectively. Results 94% and 71% of the NSCLC samples expressed GM3 and nuclear pSTAT3, respectively. Median overall survival was 40.0 months. Both low GM3 expression and high pSTAT3 expression were associated with a worse survival, which reached near significance for GM3 (P = 0.08). Microvessel density (MVD), determined by CD34 staining and morphology, was lower in NSCLC samples with high GM3 expression. CD1a+ cells (immature DCs) were more frequent in NSCLC tissues as compared to peritumoral lung tissue, while CD83+ cells (mature DCs) were more frequent in peritumoral lung tissue. CD83+ DCs were less frequent in NSCLC tissues with high GM3 expression. Conclusion GM3 and pSTAT3 are widely expressed in NSCLC. Based on CD83 expression, GM3, but not pSTAT3, appeared to be involved in tumor-induced DC suppression. pSTAT3 expression was not associated with MVD, while GM3 might play an anti-angiogenic role. Tumor immune escape and angiogenesis contribute to tumor progression, and gangliosides and activation of signal transducer and activator of transcription (STAT)-3 are implicated in these processes. As both are considered as novel therapeutic targets, we assessed the possible association of ganglioside GM3 expression and STAT3 activation with suppression of dendritic cell (DC) activation and angiogenesis in non-small cell lung cancer (NSCLC). Immunohistochemistry was performed on a tissue array to determine N-glycolyl GM3 (GM3) and phosphorylated STAT3 (pSTAT3) expression in 176 primary NSCLC resections. Median values of GM3 and pSTAT3 expression were used as cut off. Microvessel density (MVD) was determined by CD34 staining and morphology. CD1a and CD83 were used to determine infiltrating immature and mature dendritic cells, respectively. 94% and 71% of the NSCLC samples expressed GM3 and nuclear pSTAT3, respectively. Median overall survival was 40.0 months. Both low GM3 expression and high pSTAT3 expression were associated with a worse survival, which reached near significance for GM3 (P = 0.08). Microvessel density (MVD), determined by CD34 staining and morphology, was lower in NSCLC samples with high GM3 expression. CD1a+ cells (immature DCs) were more frequent in NSCLC tissues as compared to peritumoral lung tissue, while CD83+ cells (mature DCs) were more frequent in peritumoral lung tissue. CD83+ DCs were less frequent in NSCLC tissues with high GM3 expression. GM3 and pSTAT3 are widely expressed in NSCLC. Based on CD83 expression, GM3, but not pSTAT3, appeared to be involved in tumor-induced DC suppression. pSTAT3 expression was not associated with MVD, while GM3 might play an anti-angiogenic role. Background Tumor immune escape and angiogenesis contribute to tumor progression, and gangliosides and activation of signal transducer and activator of transcription (STAT)-3 are implicated in these processes. As both are considered as novel therapeutic targets, we assessed the possible association of ganglioside GM3 expression and STAT3 activation with suppression of dendritic cell (DC) activation and angiogenesis in non-small cell lung cancer (NSCLC). Methods Immunohistochemistry was performed on a tissue array to determine N -glycolyl GM3 (GM3) and phosphorylated STAT3 (pSTAT3) expression in 176 primary NSCLC resections. Median values of GM3 and pSTAT3 expression were used as cut off. Microvessel density (MVD) was determined by CD34 staining and morphology. CD1a and CD83 were used to determine infiltrating immature and mature dendritic cells, respectively. Results 94% and 71% of the NSCLC samples expressed GM3 and nuclear pSTAT3, respectively. Median overall survival was 40.0 months. Both low GM3 expression and high pSTAT3 expression were associated with a worse survival, which reached near significance for GM3 ( P = 0.08). Microvessel density (MVD), determined by CD34 staining and morphology, was lower in NSCLC samples with high GM3 expression. CD1a + cells (immature DCs) were more frequent in NSCLC tissues as compared to peritumoral lung tissue, while CD83 + cells (mature DCs) were more frequent in peritumoral lung tissue. CD83 + DCs were less frequent in NSCLC tissues with high GM3 expression. Conclusion GM3 and pSTAT3 are widely expressed in NSCLC. Based on CD83 expression, GM3, but not pSTAT3, appeared to be involved in tumor-induced DC suppression. pSTAT3 expression was not associated with MVD, while GM3 might play an anti-angiogenic role. |
| ArticleNumber | 180 |
| Audience | Academic |
| Author | van Cruijsen, Hester de Gruijl, Tanja D Giaccone, Giuseppe van der Valk, Paul Ruiz, Mariëlle Gallegos |
| AuthorAffiliation | 2 Department of Pathology, VU University Medical Center, Boelelaan 1117, 1081 HV Amsterdam, The Netherlands 3 Medical Oncology Branch, CCR, National Cancer Institute, NIH, Bethesda, MD 20892-1906, USA 1 Department of Medical Oncology, VU University Medical Center, Boelelaan 1117, 1081 HV Amsterdam, The Netherlands |
| AuthorAffiliation_xml | – name: 1 Department of Medical Oncology, VU University Medical Center, Boelelaan 1117, 1081 HV Amsterdam, The Netherlands – name: 2 Department of Pathology, VU University Medical Center, Boelelaan 1117, 1081 HV Amsterdam, The Netherlands – name: 3 Medical Oncology Branch, CCR, National Cancer Institute, NIH, Bethesda, MD 20892-1906, USA |
| Author_xml | – sequence: 1 givenname: Hester surname: van Cruijsen fullname: van Cruijsen, Hester organization: Department of Medical Oncology, VU University Medical Center – sequence: 2 givenname: Mariëlle Gallegos surname: Ruiz fullname: Ruiz, Mariëlle Gallegos organization: Department of Medical Oncology, VU University Medical Center – sequence: 3 givenname: Paul surname: van der Valk fullname: van der Valk, Paul organization: Department of Pathology, VU University Medical Center – sequence: 4 givenname: Tanja D surname: de Gruijl fullname: de Gruijl, Tanja D organization: Department of Medical Oncology, VU University Medical Center – sequence: 5 givenname: Giuseppe surname: Giaccone fullname: Giaccone, Giuseppe email: giacconeg@mail.nih.gov organization: Department of Medical Oncology, VU University Medical Center, Medical Oncology Branch, CCR, National Cancer Institute, NIH |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/19519895$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1k8tq3DAUhk1JaS7tursiKIRm4UTy3ZtCCG0aSFtopmshS8eOgkaaSHLIvHSfocczyTBTGrywOPr-38fncpjsWWchSd4zespYU52xomZpVtA6bVPW0FfJwSayt3XeTw5DuKOU1Q1t3iT7rC1Z27TlQfJnpkMYgcy19I4I78WSCCvMMuhAXE8GYQejXdAKyI90MEvpzNKQy-85gceFhxC0s6hQJOgBdSR6YYMaJfhVVMioH0R0fjJb3UmvF3ESfbqZnc9O0vyZmWLaEg9mfY6OKLDK66glkWAM3vbaoEl8_uYq6wdMAszEBh2XkwUWKQ1zgYqVzIx2IFJYzOlt8roXJsC7p_dR8vvrl9nFt_T65-XVxfl1Kqu2iqlSVVdXoqBSlJCrps5LaLoizxrFWAeQd8BkQfuedlXbdVLVTcGYqLoyb_O2qPKj5Grtq5y44wuv58IvuROarwLOD1x4_C8DvFR9XvVFgc2hRaZYR_s6k3WTK9mqpqzR6_PaazF2c1ASLJbA7Jju3lh9ywf3wLOalnk9GRw_GXh3P0KIfK7DVBlhwY2BV3VRZiXNEfy4BgeBiWG1HfrJCebnGc0alhUVQ-r0PxQ-CrAfOJ_YJNgVnOwIkInwGAcxhsCvbn7tssdb7C0IE2-DM-PU8rALftiuyqYcz6ONQLkGcERC8NBzqeNqdDBdbTijfFohPi0Jn5aEtxxXCHVn_-g21i8q6FoRkLQDeH7nRo_LEF6U_AWnCC84 |
| CitedBy_id | crossref_primary_10_1007_s10555_023_10108_z crossref_primary_10_5402_2011_848909 crossref_primary_10_1007_s10330_012_1042_5 crossref_primary_10_1007_BF03256470 crossref_primary_10_1517_14712598_2016_1157579 crossref_primary_10_3390_vaccines10050740 crossref_primary_10_1053_j_seminoncol_2018_04_003 crossref_primary_10_1111_j_1601_0825_2012_01939_x crossref_primary_10_1186_1471_2407_10_220 crossref_primary_10_1007_s11427_022_2230_4 crossref_primary_10_1177_107327481402100112 crossref_primary_10_1016_j_carres_2014_02_004 crossref_primary_10_1371_journal_pone_0182282 crossref_primary_10_1074_jbc_M116_765230 crossref_primary_10_3389_fonc_2015_00300 crossref_primary_10_1016_j_tranon_2023_101643 crossref_primary_10_1007_s11172_014_0614_7 crossref_primary_10_1371_journal_pone_0106255 crossref_primary_10_1155_2015_132326 crossref_primary_10_1007_s10719_013_9473_y crossref_primary_10_1097_gscm_0000000000000021 crossref_primary_10_1155_2013_920972 crossref_primary_10_1002_eji_201242693 crossref_primary_10_3389_fphar_2023_1282572 crossref_primary_10_1371_journal_pone_0110107 crossref_primary_10_1155_2010_961243 crossref_primary_10_2174_0929867325666180129100619 crossref_primary_10_1007_s00280_015_2710_2 crossref_primary_10_3389_fimmu_2022_994790 crossref_primary_10_1016_j_lungcan_2011_01_002 crossref_primary_10_1155_2013_602417 crossref_primary_10_1007_s10585_016_9811_0 crossref_primary_10_3389_fonc_2017_00020 crossref_primary_10_1016_j_jmb_2016_10_027 crossref_primary_10_1158_1078_0432_CCR_13_1674 crossref_primary_10_1016_j_plipres_2021_101115 crossref_primary_10_2217_imt_10_95 crossref_primary_10_3892_ol_2019_9995 crossref_primary_10_1155_2012_235418 crossref_primary_10_1007_s00262_014_1552_9 crossref_primary_10_1111_cas_12027 crossref_primary_10_1007_s00262_018_2188_y crossref_primary_10_1155_2014_482301 crossref_primary_10_1016_j_bbrc_2021_06_063 crossref_primary_10_1016_j_bbcan_2024_189176 crossref_primary_10_1007_s12032_017_1031_1 crossref_primary_10_1155_2022_4293172 crossref_primary_10_5402_2011_953803 crossref_primary_10_1007_s11172_015_1054_8 crossref_primary_10_1155_2011_245181 crossref_primary_10_1586_14737140_2014_952287 crossref_primary_10_3390_app13179922 crossref_primary_10_1111_nyas_12827 |
| Cites_doi | 10.4161/cbt.6.2.3574 10.1158/1078-0432.CCR-05-0827 10.1038/sj.onc.1206479 10.1046/j.1365-2249.2002.02006.x 10.1038/nrc1275 10.1136/jcp.2003.013508 10.1056/NEJMoa061884 10.1038/nm0798-844 10.1016/S0300-9084(03)00006-3 10.1158/1078-0432.CCR-04-1448 10.4049/jimmunol.170.7.3488 10.4161/cbt.6.12.5000 10.1111/j.1471-0528.2004.00142.x 10.1158/0008-5472.CAN-06-1572 10.1002/ijc.10915 10.1007/s10549-005-9064-0 10.1146/annurev.immunol.25.022106.141609 10.1038/nri1498 10.3109/00313029309090853 10.1089/02724570050109639 10.3109/02841869709001284 10.1056/NEJM197108122850711 10.1002/(SICI)1097-0215(19990730)82:3<412::AID-IJC15>3.0.CO;2-J 10.3322/canjclin.57.1.43 10.1038/nm976 10.1200/JCO.2003.02.124 10.1038/sj.onc.1205260 10.1084/jem.190.10.1417 10.1016/j.lungcan.2006.11.003 10.1093/intimm/dxl024 10.1016/S0959-8049(99)00327-5 10.1002/(SICI)1096-9896(199908)188:4<369::AID-PATH381>3.0.CO;2-X 10.1056/NEJM199101033240101 10.1182/blood.V75.7.1564.1564 |
| ContentType | Journal Article |
| Copyright | van Cruijsen et al; licensee BioMed Central Ltd. 2009 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. COPYRIGHT 2009 BioMed Central Ltd. Copyright ©2009 van Cruijsen et al; licensee BioMed Central Ltd. 2009 van Cruijsen et al; licensee BioMed Central Ltd. |
| Copyright_xml | – notice: van Cruijsen et al; licensee BioMed Central Ltd. 2009 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. – notice: COPYRIGHT 2009 BioMed Central Ltd. – notice: Copyright ©2009 van Cruijsen et al; licensee BioMed Central Ltd. 2009 van Cruijsen et al; licensee BioMed Central Ltd. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM ISR 7X8 5PM DOA |
| DOI | 10.1186/1471-2407-9-180 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Science MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2407 |
| EndPage | 180 |
| ExternalDocumentID | oai_doaj_org_article_5df36f44017042d1b0f72c783dc9d857 PMC2705377 A202812461 19519895 10_1186_1471_2407_9_180 |
| Genre | Journal Article |
| GeographicLocations | United States Netherlands |
| GeographicLocations_xml | – name: Netherlands – name: United States |
| GroupedDBID | --- 0R~ 23N 2VQ 2WC 4.4 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHSBF AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C1A C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EJD EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR IHW INH INR IPNFZ ISR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RIG RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS U2A UKHRP W2D WOQ WOW XSB AAYXX AFFHD CITATION ALIPV CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c696t-dd6b76a40ca5e3d8735e8b4328d11bee3be1c40ff0b69bbcd78411a6b53939463 |
| IEDL.DBID | RSV |
| ISICitedReferencesCount | 68 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000268495000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1471-2407 |
| IngestDate | Tue Oct 14 19:06:04 EDT 2025 Tue Nov 04 01:56:43 EST 2025 Sun Nov 09 12:01:45 EST 2025 Tue Nov 11 11:00:29 EST 2025 Tue Nov 04 18:22:16 EST 2025 Thu Nov 13 16:36:53 EST 2025 Thu May 22 21:23:30 EDT 2025 Mon Jul 21 05:42:05 EDT 2025 Tue Nov 18 22:21:34 EST 2025 Sat Nov 29 04:29:09 EST 2025 Sat Sep 06 07:24:39 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Vascular Endothelial Growth Factor pSTAT3 Expression NSCLC Patient NSCLC Tissue NSCLC Sample |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c696t-dd6b76a40ca5e3d8735e8b4328d11bee3be1c40ff0b69bbcd78411a6b53939463 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://link.springer.com/10.1186/1471-2407-9-180 |
| PMID | 19519895 |
| PQID | 67452503 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_5df36f44017042d1b0f72c783dc9d857 pubmedcentral_primary_oai_pubmedcentral_nih_gov_2705377 proquest_miscellaneous_67452503 gale_infotracmisc_A202812461 gale_infotracacademiconefile_A202812461 gale_incontextgauss_ISR_A202812461 gale_healthsolutions_A202812461 pubmed_primary_19519895 crossref_citationtrail_10_1186_1471_2407_9_180 crossref_primary_10_1186_1471_2407_9_180 springer_journals_10_1186_1471_2407_9_180 |
| PublicationCentury | 2000 |
| PublicationDate | 2009-06-11 |
| PublicationDateYYYYMMDD | 2009-06-11 |
| PublicationDate_xml | – month: 06 year: 2009 text: 2009-06-11 day: 11 |
| PublicationDecade | 2000 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | BMC cancer |
| PublicationTitleAbbrev | BMC Cancer |
| PublicationTitleAlternate | BMC Cancer |
| PublicationYear | 2009 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | Mineo, Ambrogi, Baldi, Rabitti, Bollero, Vincenzi, Tonini (CR29) 2004; 57 Alessandri, Cornaglia-Ferraris, Gullino (CR16) 1997; 36 Carr, Mullet, Mazorra, Vazquez, Alfonso, Mesa, Rengifo, Perez, Fernandez (CR7) 2000; 19 Zeid, Muller (CR33) 1993; 25 Oliva, Valdes, Casaco, Pimentel, Gonzalez, Alvarez, Osorio, Velazco, Figueroa, Ortiz, Escobar, Orozco, Cruz, Franco, Diaz, Roque, Carr, Vazquez, Mateos, Rubio, Perez, Fernandez (CR39) 2006; 96 Yu, Jove (CR19) 2004; 4 Kawai, Kato, Higashi, Kato, Naiki (CR6) 1991; 51 Santin, Ravindranath, Bellone, Muthugounder, Palmieri, O'Brien, Roman, Cannon, Pecorelli (CR9) 2004; 111 Niu, Wright, Huang, Song, Haura, Turkson, Zhang, Wang, Sinibaldi, Coppola, Heller, Ellis, Karras, Bromberg, Pardoll, Jove, Yu (CR23) 2002; 21 Valentino, Moss, Olson, Wang, Elashoff, Ladisch (CR8) 1990; 75 Peguet-Navarro, Sportouch, Popa, Berthier, Schmitt, Portoukalian (CR11) 2003; 170 Wang, Niu, Kortylewski, Burdelya, Shain, Zhang, Bhattacharya, Gabrilovich, Heller, Coppola, Dalton, Jove, Pardoll, Yu (CR22) 2004; 10 Alfonso, Diaz, de la, Santiesteban, Aguirre, Perez, Rodriguez, Barroso, Hernandez, Toledo, Gabri, Alonso, Viada, Gomez, Suarez, Vazquez, Perez, Macias (CR35) 2007; 6 Neninger, Diaz, de la, Rives, Diaz, Saurez, Gabri, Alonso, Wilkinson, Alfonso, Combet, Perez, Vazquez (CR36) 2007; 6 Jemal, Siegel, Ward, Murray, Xu, Thun (CR1) 2007; 57 Weidner, Semple, Welch, Folkman (CR34) 1991; 324 Folkman (CR4) 1971; 285 Sandel, Dadabayev, Menon, Morreau, Melief, Offringa, Burg, Janssen-van Rhijn, Ensink, Tollenaar, Velde, Kuppen (CR26) 2005; 11 Iwamoto, Shinohara, Miyamoto, Okuzawa, Mabuchi, Nohara, Gon, Toyoda, Tanigawa (CR25) 2003; 104 Liu, McCarthy, Ladisch (CR17) 2006; 66 Inoshima, Nakanishi, Minami, Izumi, Takayama, Yoshino, Nobuyuki (CR32) 2002; 8 Birkle, Zeng, Gao, Yu, Aubry (CR5) 2003; 85 Kononen, Bubendorf, Kallioniemi, Barlund, Schraml, Leighton, Torhorst, Mihatsch, Sauter, Kallioniemi (CR24) 1998; 4 Slevin, Kumar, He, Gaffney (CR18) 1999; 82 Haura, Zheng, Song, Cantor, Bepler (CR20) 2005; 11 Song, Turkson, Karras, Jove, Haura (CR21) 2003; 22 Bell, Chomarat, Broyles, Netto, Harb, Lebecque, Valladeau, Davoust, Palucka, Banchereau (CR27) 1999; 190 Yano, Tanikawa, Fujie, Masutani, Horie (CR28) 2000; 36 Bennaceur, Popa, Portoukalian, Berthier-Vergnes, Peguet-Navarro (CR13) 2006; 18 Rabinovich, Gabrilovich, Sotomayor (CR3) 2007; 25 Bitton, Guthmann, Gabri, Carnero, Alonso, Fainboim, Gomez (CR38) 2002; 9 Shurin, Shurin, Bykovskaia, Shogan, Lotze, Barksdale (CR10) 2001; 61 Carr, Rodriguez, Arango, Camacho, Osorio, Gabri, Carrillo, Valdes, Bebelagua, Perez, Fernandez (CR37) 2003; 21 Sandler, Gray, Perry, Brahmer, Schiller, Dowlati, Lilenbaum, Johnson (CR2) 2006; 355 Wolfl, Batten, Posovszky, Bernhard, Berthold (CR14) 2002; 130 Decaussin, Sartelet, Robert, Moro, Claraz, Brambilla, Brambilla (CR30) 1999; 188 Gabrilovich (CR12) 2004; 4 Ziche, Morbidelli, Alessandri, Gullino (CR15) 1992; 67 Cortas, Eisenberg, Fu, Kern, Patrick, Dowlati (CR31) 2007; 55 GA Rabinovich (1514_CR3) 2007; 25 M Wolfl (1514_CR14) 2002; 130 N Inoshima (1514_CR32) 2002; 8 EB Haura (1514_CR20) 2005; 11 AD Santin (1514_CR9) 2004; 111 A Sandler (1514_CR2) 2006; 355 GV Shurin (1514_CR10) 2001; 61 H Yu (1514_CR19) 2004; 4 MH Sandel (1514_CR26) 2005; 11 L Valentino (1514_CR8) 1990; 75 G Alessandri (1514_CR16) 1997; 36 K Bennaceur (1514_CR13) 2006; 18 M Slevin (1514_CR18) 1999; 82 T Yano (1514_CR28) 2000; 36 M Decaussin (1514_CR30) 1999; 188 RJ Bitton (1514_CR38) 2002; 9 S Alfonso (1514_CR35) 2007; 6 D Bell (1514_CR27) 1999; 190 T Wang (1514_CR22) 2004; 10 M Iwamoto (1514_CR25) 2003; 104 A Jemal (1514_CR1) 2007; 57 S Birkle (1514_CR5) 2003; 85 T Cortas (1514_CR31) 2007; 55 L Song (1514_CR21) 2003; 22 J Kononen (1514_CR24) 1998; 4 TC Mineo (1514_CR29) 2004; 57 J Folkman (1514_CR4) 1971; 285 T Kawai (1514_CR6) 1991; 51 J Peguet-Navarro (1514_CR11) 2003; 170 G Niu (1514_CR23) 2002; 21 N Weidner (1514_CR34) 1991; 324 A Carr (1514_CR7) 2000; 19 M Ziche (1514_CR15) 1992; 67 NA Zeid (1514_CR33) 1993; 25 D Gabrilovich (1514_CR12) 2004; 4 A Carr (1514_CR37) 2003; 21 Y Liu (1514_CR17) 2006; 66 E Neninger (1514_CR36) 2007; 6 JP Oliva (1514_CR39) 2006; 96 10440746 - J Pathol. 1999 Aug;188(4):369-77 15814636 - Clin Cancer Res. 2005 Apr 1;11(7):2576-82 11196188 - Cancer Res. 2001 Jan 1;61(1):363-9 11960372 - Oncogene. 2002 Mar 27;21(13):2000-8 1281244 - Lab Invest. 1992 Dec;67(6):711-5 10399959 - Int J Cancer. 1999 Jul 30;82(3):412-23 15573129 - Nat Rev Immunol. 2004 Dec;4(12):941-52 17134371 - Annu Rev Immunol. 2007;25:267-96 10738124 - Eur J Cancer. 2000 Mar;36(5):601-9 10952412 - Hybridoma. 2000 Jun;19(3):241-7 16322892 - Breast Cancer Res Treat. 2006 Mar;96(2):115-21 17167137 - N Engl J Med. 2006 Dec 14;355(24):2542-50 12833138 - Oncogene. 2003 Jul 3;22(27):4150-65 15166262 - J Clin Pathol. 2004 Jun;57(6):591-7 4938153 - N Engl J Med. 1971 Nov 18;285(21):1182-6 12452834 - Clin Exp Immunol. 2002 Dec;130(3):441-8 14702634 - Nat Med. 2004 Jan;10(1):48-54 15198791 - BJOG. 2004 Jun;111(6):613-8 18075301 - Cancer Biol Ther. 2007 Dec;6(12):1847-52 12770784 - Biochimie. 2003 Mar-Apr;85(3-4):455-63 1997165 - Cancer Res. 1991 Feb 15;51(4):1242-6 8164994 - Pathology. 1993 Oct;25(4):338-43 16675488 - Int Immunol. 2006 Jun;18(6):879-86 12637465 - J Clin Oncol. 2003 Mar 15;21(6):1015-21 2317562 - Blood. 1990 Apr 1;75(7):1564-7 14964307 - Nat Rev Cancer. 2004 Feb;4(2):97-105 10562317 - J Exp Med. 1999 Nov 15;190(10):1417-26 12646609 - J Immunol. 2003 Apr 1;170(7):3488-94 17161498 - Lung Cancer. 2007 Mar;55(3):349-55 1701519 - N Engl J Med. 1991 Jan 3;324(1):1-8 9247098 - Acta Oncol. 1997;36(4):383-7 9662379 - Nat Med. 1998 Jul;4(7):844-7 11836591 - Oncol Rep. 2002 Mar-Apr;9(2):267-76 12429638 - Clin Cancer Res. 2002 Nov;8(11):3480-6 17237035 - CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 17079461 - Cancer Res. 2006 Nov 1;66(21):10408-14 16322287 - Clin Cancer Res. 2005 Dec 1;11(23):8288-94 12532424 - Int J Cancer. 2003 Mar 10;104(1):92-7 17218777 - Cancer Biol Ther. 2007 Feb;6(2):145-50 |
| References_xml | – volume: 67 start-page: 711 year: 1992 end-page: 715 ident: CR15 article-title: Angiogenesis can be stimulated or repressed in vivo by a change in GM3:GD3 ganglioside ratio publication-title: Lab Invest – volume: 6 start-page: 145 year: 2007 end-page: 150 ident: CR36 article-title: Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial publication-title: Cancer Biol Ther doi: 10.4161/cbt.6.2.3574 – volume: 11 start-page: 8288 year: 2005 end-page: 8294 ident: CR20 article-title: Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-05-0827 – volume: 22 start-page: 4150 year: 2003 end-page: 4165 ident: CR21 article-title: Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells publication-title: Oncogene doi: 10.1038/sj.onc.1206479 – volume: 9 start-page: 267 year: 2002 end-page: 276 ident: CR38 article-title: Cancer vaccines: an update with special focus on ganglioside antigens publication-title: Oncol Rep – volume: 130 start-page: 441 year: 2002 end-page: 448 ident: CR14 article-title: Gangliosides inhibit the development from monocytes to dendritic cells publication-title: Clin Exp Immunol doi: 10.1046/j.1365-2249.2002.02006.x – volume: 4 start-page: 97 year: 2004 end-page: 105 ident: CR19 article-title: The STATs of cancer – new molecular targets come of age publication-title: Nat Rev Cancer doi: 10.1038/nrc1275 – volume: 57 start-page: 591 year: 2004 end-page: 597 ident: CR29 article-title: Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer publication-title: J Clin Pathol doi: 10.1136/jcp.2003.013508 – volume: 355 start-page: 2542 year: 2006 end-page: 2550 ident: CR2 article-title: Paclitaxel-Carboplatin Alone or with Bevacizumab for Non-Small-Cell Lung Cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa061884 – volume: 4 start-page: 844 year: 1998 end-page: 847 ident: CR24 article-title: Tissue microarrays for high-throughput molecular profiling of tumor specimens publication-title: Nat Med doi: 10.1038/nm0798-844 – volume: 85 start-page: 455 year: 2003 end-page: 463 ident: CR5 article-title: Role of tumor-associated gangliosides in cancer progression publication-title: Biochimie doi: 10.1016/S0300-9084(03)00006-3 – volume: 11 start-page: 2576 year: 2005 end-page: 2582 ident: CR26 article-title: Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-04-1448 – volume: 170 start-page: 3488 year: 2003 end-page: 3494 ident: CR11 article-title: Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis publication-title: J Immunol doi: 10.4049/jimmunol.170.7.3488 – volume: 6 start-page: 1847 issue: 12 year: 2007 end-page: 52 ident: CR35 article-title: 1E10 Anti-Idiotype Vaccine in Non-Small Cell Lung Cancer: Experience in Stage IIIb/IV Patients publication-title: Cancer Biol Ther doi: 10.4161/cbt.6.12.5000 – volume: 75 start-page: 1564 year: 1990 end-page: 1567 ident: CR8 article-title: Shed tumor gangliosides and progression of human neuroblastoma publication-title: Blood – volume: 111 start-page: 613 year: 2004 end-page: 618 ident: CR9 article-title: Increased levels of gangliosides in the plasma and ascitic fluid of patients with advanced ovarian cancer publication-title: BJOG doi: 10.1111/j.1471-0528.2004.00142.x – volume: 66 start-page: 10408 year: 2006 end-page: 10414 ident: CR17 article-title: Membrane ganglioside enrichment lowers the threshold for vascular endothelial cell angiogenic signaling publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-06-1572 – volume: 104 start-page: 92 year: 2003 end-page: 97 ident: CR25 article-title: Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas publication-title: Int J Cancer doi: 10.1002/ijc.10915 – volume: 96 start-page: 115 year: 2006 end-page: 121 ident: CR39 article-title: Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with (99m)Tc publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-005-9064-0 – volume: 25 start-page: 267 year: 2007 end-page: 296 ident: CR3 article-title: Immunosuppressive strategies that are mediated by tumor cells publication-title: Annu Rev Immunol doi: 10.1146/annurev.immunol.25.022106.141609 – volume: 4 start-page: 941 year: 2004 end-page: 952 ident: CR12 article-title: Mechanisms and functional significance of tumour-induced dendritic-cell defects publication-title: Nat Rev Immunol doi: 10.1038/nri1498 – volume: 25 start-page: 338 year: 1993 end-page: 343 ident: CR33 article-title: S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival publication-title: Pathology doi: 10.3109/00313029309090853 – volume: 19 start-page: 241 year: 2000 end-page: 247 ident: CR7 article-title: A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors publication-title: Hybridoma doi: 10.1089/02724570050109639 – volume: 61 start-page: 363 year: 2001 end-page: 369 ident: CR10 article-title: Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function publication-title: Cancer Res – volume: 36 start-page: 383 year: 1997 end-page: 387 ident: CR16 article-title: Angiogenic and angiostatic microenvironment in tumors – role of gangliosides publication-title: Acta Oncol doi: 10.3109/02841869709001284 – volume: 285 start-page: 1182 year: 1971 end-page: 1186 ident: CR4 article-title: Tumor angiogenesis: therapeutic implications publication-title: N Engl J Med doi: 10.1056/NEJM197108122850711 – volume: 82 start-page: 412 year: 1999 end-page: 423 ident: CR18 article-title: Physiological concentrations of gangliosides GM1, GM2 and GM3 differentially modify basic-fibroblast-growth-factor-induced mitogenesis and the associated signalling pathway in endothelial cells publication-title: Int J Cancer doi: 10.1002/(SICI)1097-0215(19990730)82:3<412::AID-IJC15>3.0.CO;2-J – volume: 8 start-page: 3480 year: 2002 end-page: 3486 ident: CR32 article-title: The Influence of Dendritic Cell Infiltration and Vascular Endothelial Growth Factor Expression on the Prognosis of Non-Small Cell Lung Cancer publication-title: Clin Cancer Res – volume: 57 start-page: 43 year: 2007 end-page: 66 ident: CR1 article-title: Cancer statistics, 2007 publication-title: CA Cancer J Clin doi: 10.3322/canjclin.57.1.43 – volume: 10 start-page: 48 year: 2004 end-page: 54 ident: CR22 article-title: Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells publication-title: Nat Med doi: 10.1038/nm976 – volume: 21 start-page: 1015 year: 2003 end-page: 1021 ident: CR37 article-title: Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine publication-title: J Clin Oncol doi: 10.1200/JCO.2003.02.124 – volume: 21 start-page: 2000 year: 2002 end-page: 2008 ident: CR23 article-title: Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis publication-title: Oncogene doi: 10.1038/sj.onc.1205260 – volume: 190 start-page: 1417 year: 1999 end-page: 1426 ident: CR27 article-title: In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas publication-title: J Exp Med doi: 10.1084/jem.190.10.1417 – volume: 55 start-page: 349 year: 2007 end-page: 355 ident: CR31 article-title: Activation state EGFR and STAT-3 as prognostic markers in resected non-small cell lung cancer publication-title: Lung Cancer doi: 10.1016/j.lungcan.2006.11.003 – volume: 18 start-page: 879 year: 2006 end-page: 886 ident: CR13 article-title: Melanoma-derived gangliosides impair migratory and antigen-presenting function of human epidermal Langerhans cells and induce their apoptosis publication-title: Int Immunol doi: 10.1093/intimm/dxl024 – volume: 36 start-page: 601 year: 2000 end-page: 609 ident: CR28 article-title: Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer publication-title: Eur J Cancer doi: 10.1016/S0959-8049(99)00327-5 – volume: 51 start-page: 1242 year: 1991 end-page: 1246 ident: CR6 article-title: Quantitative determination of N-glycolylneuraminic acid expression in human cancerous tissues and avian lymphoma cell lines as a tumor-associated sialic acid by gas chromatography-mass spectrometry publication-title: Cancer Res – volume: 188 start-page: 369 year: 1999 end-page: 377 ident: CR30 article-title: Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival publication-title: J Pathol doi: 10.1002/(SICI)1096-9896(199908)188:4<369::AID-PATH381>3.0.CO;2-X – volume: 324 start-page: 1 year: 1991 end-page: 8 ident: CR34 article-title: Tumor angiogenesis and metastasis – correlation in invasive breast carcinoma publication-title: N Engl J Med doi: 10.1056/NEJM199101033240101 – volume: 10 start-page: 48 year: 2004 ident: 1514_CR22 publication-title: Nat Med doi: 10.1038/nm976 – volume: 57 start-page: 591 year: 2004 ident: 1514_CR29 publication-title: J Clin Pathol doi: 10.1136/jcp.2003.013508 – volume: 55 start-page: 349 year: 2007 ident: 1514_CR31 publication-title: Lung Cancer doi: 10.1016/j.lungcan.2006.11.003 – volume: 25 start-page: 338 year: 1993 ident: 1514_CR33 publication-title: Pathology doi: 10.3109/00313029309090853 – volume: 188 start-page: 369 year: 1999 ident: 1514_CR30 publication-title: J Pathol doi: 10.1002/(SICI)1096-9896(199908)188:4<369::AID-PATH381>3.0.CO;2-X – volume: 4 start-page: 941 year: 2004 ident: 1514_CR12 publication-title: Nat Rev Immunol doi: 10.1038/nri1498 – volume: 11 start-page: 2576 year: 2005 ident: 1514_CR26 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-04-1448 – volume: 61 start-page: 363 year: 2001 ident: 1514_CR10 publication-title: Cancer Res – volume: 21 start-page: 1015 year: 2003 ident: 1514_CR37 publication-title: J Clin Oncol doi: 10.1200/JCO.2003.02.124 – volume: 355 start-page: 2542 year: 2006 ident: 1514_CR2 publication-title: N Engl J Med doi: 10.1056/NEJMoa061884 – volume: 4 start-page: 844 year: 1998 ident: 1514_CR24 publication-title: Nat Med doi: 10.1038/nm0798-844 – volume: 285 start-page: 1182 year: 1971 ident: 1514_CR4 publication-title: N Engl J Med doi: 10.1056/NEJM197108122850711 – volume: 25 start-page: 267 year: 2007 ident: 1514_CR3 publication-title: Annu Rev Immunol doi: 10.1146/annurev.immunol.25.022106.141609 – volume: 57 start-page: 43 year: 2007 ident: 1514_CR1 publication-title: CA Cancer J Clin doi: 10.3322/canjclin.57.1.43 – volume: 36 start-page: 601 year: 2000 ident: 1514_CR28 publication-title: Eur J Cancer doi: 10.1016/S0959-8049(99)00327-5 – volume: 18 start-page: 879 year: 2006 ident: 1514_CR13 publication-title: Int Immunol doi: 10.1093/intimm/dxl024 – volume: 67 start-page: 711 year: 1992 ident: 1514_CR15 publication-title: Lab Invest – volume: 6 start-page: 1847 issue: 12 year: 2007 ident: 1514_CR35 publication-title: Cancer Biol Ther doi: 10.4161/cbt.6.12.5000 – volume: 82 start-page: 412 year: 1999 ident: 1514_CR18 publication-title: Int J Cancer doi: 10.1002/(SICI)1097-0215(19990730)82:3<412::AID-IJC15>3.0.CO;2-J – volume: 4 start-page: 97 year: 2004 ident: 1514_CR19 publication-title: Nat Rev Cancer doi: 10.1038/nrc1275 – volume: 190 start-page: 1417 year: 1999 ident: 1514_CR27 publication-title: J Exp Med doi: 10.1084/jem.190.10.1417 – volume: 96 start-page: 115 year: 2006 ident: 1514_CR39 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-005-9064-0 – volume: 22 start-page: 4150 year: 2003 ident: 1514_CR21 publication-title: Oncogene doi: 10.1038/sj.onc.1206479 – volume: 111 start-page: 613 year: 2004 ident: 1514_CR9 publication-title: BJOG doi: 10.1111/j.1471-0528.2004.00142.x – volume: 324 start-page: 1 year: 1991 ident: 1514_CR34 publication-title: N Engl J Med doi: 10.1056/NEJM199101033240101 – volume: 8 start-page: 3480 year: 2002 ident: 1514_CR32 publication-title: Clin Cancer Res – volume: 21 start-page: 2000 year: 2002 ident: 1514_CR23 publication-title: Oncogene doi: 10.1038/sj.onc.1205260 – volume: 130 start-page: 441 year: 2002 ident: 1514_CR14 publication-title: Clin Exp Immunol doi: 10.1046/j.1365-2249.2002.02006.x – volume: 170 start-page: 3488 year: 2003 ident: 1514_CR11 publication-title: J Immunol doi: 10.4049/jimmunol.170.7.3488 – volume: 9 start-page: 267 year: 2002 ident: 1514_CR38 publication-title: Oncol Rep – volume: 19 start-page: 241 year: 2000 ident: 1514_CR7 publication-title: Hybridoma doi: 10.1089/02724570050109639 – volume: 104 start-page: 92 year: 2003 ident: 1514_CR25 publication-title: Int J Cancer doi: 10.1002/ijc.10915 – volume: 75 start-page: 1564 year: 1990 ident: 1514_CR8 publication-title: Blood doi: 10.1182/blood.V75.7.1564.1564 – volume: 66 start-page: 10408 year: 2006 ident: 1514_CR17 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-06-1572 – volume: 6 start-page: 145 year: 2007 ident: 1514_CR36 publication-title: Cancer Biol Ther doi: 10.4161/cbt.6.2.3574 – volume: 36 start-page: 383 year: 1997 ident: 1514_CR16 publication-title: Acta Oncol doi: 10.3109/02841869709001284 – volume: 85 start-page: 455 year: 2003 ident: 1514_CR5 publication-title: Biochimie doi: 10.1016/S0300-9084(03)00006-3 – volume: 51 start-page: 1242 year: 1991 ident: 1514_CR6 publication-title: Cancer Res – volume: 11 start-page: 8288 year: 2005 ident: 1514_CR20 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-05-0827 – reference: 17218777 - Cancer Biol Ther. 2007 Feb;6(2):145-50 – reference: 10440746 - J Pathol. 1999 Aug;188(4):369-77 – reference: 11960372 - Oncogene. 2002 Mar 27;21(13):2000-8 – reference: 15814636 - Clin Cancer Res. 2005 Apr 1;11(7):2576-82 – reference: 2317562 - Blood. 1990 Apr 1;75(7):1564-7 – reference: 11836591 - Oncol Rep. 2002 Mar-Apr;9(2):267-76 – reference: 17134371 - Annu Rev Immunol. 2007;25:267-96 – reference: 16322892 - Breast Cancer Res Treat. 2006 Mar;96(2):115-21 – reference: 10399959 - Int J Cancer. 1999 Jul 30;82(3):412-23 – reference: 4938153 - N Engl J Med. 1971 Nov 18;285(21):1182-6 – reference: 15573129 - Nat Rev Immunol. 2004 Dec;4(12):941-52 – reference: 14702634 - Nat Med. 2004 Jan;10(1):48-54 – reference: 15166262 - J Clin Pathol. 2004 Jun;57(6):591-7 – reference: 17237035 - CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 – reference: 12429638 - Clin Cancer Res. 2002 Nov;8(11):3480-6 – reference: 12770784 - Biochimie. 2003 Mar-Apr;85(3-4):455-63 – reference: 10562317 - J Exp Med. 1999 Nov 15;190(10):1417-26 – reference: 11196188 - Cancer Res. 2001 Jan 1;61(1):363-9 – reference: 15198791 - BJOG. 2004 Jun;111(6):613-8 – reference: 12646609 - J Immunol. 2003 Apr 1;170(7):3488-94 – reference: 14964307 - Nat Rev Cancer. 2004 Feb;4(2):97-105 – reference: 12637465 - J Clin Oncol. 2003 Mar 15;21(6):1015-21 – reference: 1281244 - Lab Invest. 1992 Dec;67(6):711-5 – reference: 8164994 - Pathology. 1993 Oct;25(4):338-43 – reference: 17161498 - Lung Cancer. 2007 Mar;55(3):349-55 – reference: 12452834 - Clin Exp Immunol. 2002 Dec;130(3):441-8 – reference: 1701519 - N Engl J Med. 1991 Jan 3;324(1):1-8 – reference: 17079461 - Cancer Res. 2006 Nov 1;66(21):10408-14 – reference: 10952412 - Hybridoma. 2000 Jun;19(3):241-7 – reference: 9662379 - Nat Med. 1998 Jul;4(7):844-7 – reference: 16322287 - Clin Cancer Res. 2005 Dec 1;11(23):8288-94 – reference: 12833138 - Oncogene. 2003 Jul 3;22(27):4150-65 – reference: 16675488 - Int Immunol. 2006 Jun;18(6):879-86 – reference: 9247098 - Acta Oncol. 1997;36(4):383-7 – reference: 12532424 - Int J Cancer. 2003 Mar 10;104(1):92-7 – reference: 18075301 - Cancer Biol Ther. 2007 Dec;6(12):1847-52 – reference: 1997165 - Cancer Res. 1991 Feb 15;51(4):1242-6 – reference: 10738124 - Eur J Cancer. 2000 Mar;36(5):601-9 – reference: 17167137 - N Engl J Med. 2006 Dec 14;355(24):2542-50 |
| SSID | ssj0017808 |
| Score | 2.2168188 |
| Snippet | Background
Tumor immune escape and angiogenesis contribute to tumor progression, and gangliosides and activation of signal transducer and activator of... Tumor immune escape and angiogenesis contribute to tumor progression, and gangliosides and activation of signal transducer and activator of transcription... Background Tumor immune escape and angiogenesis contribute to tumor progression, and gangliosides and activation of signal transducer and activator of... Abstract Background Tumor immune escape and angiogenesis contribute to tumor progression, and gangliosides and activation of signal transducer and activator of... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 180 |
| SubjectTerms | Biomedical and Life Sciences Biomedicine Cancer Research Carcinoma, Non-Small-Cell Lung - blood supply Carcinoma, Non-Small-Cell Lung - immunology Dendritic cells Dendritic Cells - immunology Dendritic Cells - pathology Female G(M3) Ganglioside - biosynthesis G(M3) Ganglioside - immunology Genetic aspects Genetic transcription Health Promotion and Disease Prevention Humans Immunohistochemistry Lung cancer, Non-small cell Lung Neoplasms - blood supply Lung Neoplasms - immunology Male Medicine/Public Health Microvessels - immunology Microvessels - pathology Middle Aged Neovascularization, Pathologic - immunology Neovascularization, Pathologic - pathology Oncology Physiological aspects Research Article Risk factors STAT3 Transcription Factor - biosynthesis STAT3 Transcription Factor - immunology Surgical Oncology Tissue Array Analysis Tissue microarrays |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQhRAXxJuFQi2ERHswXceJHR8XRAGJrhBdUG-WH8l2pTRB2YfYP81vwON4l01RxYWrPXaSyefxWDP-BqFXhuZDrZ0lPLGSpN7BIN6rloQXTqT-hzMTsny_fxbjcX5-Lr_slPqCnLCOHrhT3HHmSsbLNAWelzRx1AxLkViRM2ely7Nwj9x7PZvDVIwfiDzUoqPe9EL8QERSH5rz420bkYQCG-TOfhRo-_82zju709XMySvh07ArndxFd6I7iUfdZ9xDN4r6Prp1GgPmD9CvSVAsvoS8O6zbVq-xjjwkuCnxVMM13gZqduIxmVZrj4t1hT-cMlz8jDmytR_hMCR6-CctYG9zHg9taIVrESs4t8NkoW9jhfDh2WQ0OSJsIwNtsxq3MfsOLxrsbZ4LpRYwxA98bzmrIo1vmD289QrYzSuQhfQRmKJuajK_1H5EGFZ5e4UtoLd9iL6dvJ-8-0hiiQdiueQL4hw3gut0aHVWMJcLlhW5SVmSO0pNUTBTUJsOy3JouDTGOgiTUs1NxiSTKWeP0J5_aPEE4bygHApxMZ3JVJaJNDwzTniHx2_A2g0H6M3mRysb-c-hDEelwjko5wqQoQAZSiqPjAE63A740VF_XC_6FpCzFQPO7tDgkawiktW_kDxAB4A71V2A3VoeNUq8D0iB92-AXgYJ4O2oITFoqpfzufp09rUn9DoKlY3_PqvjPQuvJaD66knu9yS9YbG97oPNAlDQBdl4ddEs54qLEA1nA_S4Ww5_9OMddpnLbIBEb6H0NNPvqWcXgdU8EUAt5LVwtFlSKprT-XVqf_o_1P4M3e4ihJxQuo_2Fu2yeI5u2tViNm9fBLPyG69gewc priority: 102 providerName: Directory of Open Access Journals |
| Title | Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer |
| URI | https://link.springer.com/article/10.1186/1471-2407-9-180 https://www.ncbi.nlm.nih.gov/pubmed/19519895 https://www.proquest.com/docview/67452503 https://pubmed.ncbi.nlm.nih.gov/PMC2705377 https://doaj.org/article/5df36f44017042d1b0f72c783dc9d857 |
| Volume | 9 |
| WOSCitedRecordID | wos000268495000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMed Central Open Access Free customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: RBZ dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: Directory of Open Access Journals customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: DOA dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: M~E dateStart: 20010101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Publicly Available Content Database customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: Springer LINK customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: RSV dateStart: 20011201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZ2QYgX7pfC6CyExPZgSOLEl8cNbTCJVdVWpvFk-ZKUSl2C0nZif5rfgI-bFDLYA7xUqn1sp8fnlp7jzwi9NrGItHaWsMRKkvoAg_ioWhKWO576DacmVPmefeKDgTg_l8M1FLdnYUK1e5uSDJY6qLVg72JvRiEXwIkkfoF1tOl9nQBdPDk9WyUOuIhEg-Dzl0Ed5xMw-v-0xL-5outlktdypcEFHd77j4e_j-428SbeWwrIA7SWlw_R7eMmo_4I_RgFzuMLKMzDuq71FdYNUAmuCjzWcM63gks98YCMp1decK6m-MMxxfn3poi29CMchkoQv9IcnJ_zAlOHVjg3cQkv9jBZ6GvNFN45He2NdgltaaBtUuK6Kc_D8wp7o-jCXQwYEgy-t5hMG5zfMHt46kuAP58CLdSXwBRlVZLZhfYjwrCpN2jYgnjXj9Hnw4PR-4-kuQOCWCbZnDjHDGc6jazOcuoEp1kuTEoT4eLY5Dk1eWzTqCgiw6Qx1kEeNdbMZFRSmTL6BG34RfNnCIs8ZnBTF9WZTGWRSMMy47iPiLyH1i7qobetcCjbAKTDPR1TFV6UBFOwiwp2UUnld7GHdlYDvi2xQW4m3QdpW5EBqHdoqOqxamyEylxBWZGmAGmUJi42UcETywV1VjqR8R7aBllVyxOyK9Ok9hIfJMYADNhDrwIFAHuUUDk01ovZTB2dnnSI3jREReV_n9XNQQzPJcAC61BudSi95bGd7u1WaRR0QblemVeLmWI8pMtpDz1dqtAv_viIXgqZ9RDvKFeHM92ecvI1wJ4nHLCHPBd2WxVTjb2d3cT25_9A-wLdWWYKGYnjLbQxrxf5S3TLXs4ns7qP1vk5D5-ijzb3DwbDk374_8Z_Gx4dD7_0gx36CXX5gYk |
| linkProvider | Springer Nature |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZKQcCFZ4GFQi2ERHswJHHix7EgSivaFWqXqjfLj2RZaZug7Laif5rfgMfrLKTQA1ztsZOMxzMTzefPCL0yqUi0dpawzEqS-wSD-KxaElY6nvsFpyagfI_3-XAoTk7k5xWUdmdhAtq9K0kGTx22tWBvU-9GoRbAiST-AdfQ9dyHK0DxHR4dLwsHXCQiMvj8ZVAv-ASO_j898W-h6DJM8lKtNISgnbv_8fL30J2Yb-LthYHcRytl_QDdPIgV9YfoxyhoHp8CMA_rttUXWEeiEtxUeKzhnG8Dl3riIRlPL7zhXEzxxwOKy-8RRFv7EQ4DEsQ_aQ7Bz3mDaUMrnJs4hx97mCz0dW4Kbx6NtkdbhHYy0DapcRvheXjeYO8UXbiLAUOBwfdWk2nk-Q2zh7c-B_rzKcgCvgSmqJuazE61HxGGTb1DwxbMu11DX3Y-jN7vkngHBLFMsjlxjhnOdJ5YXZTUCU6LUpicZsKlqSlLasrU5klVJYZJY6yDOmqqmSmopDJn9BFa9Q8tnyAsypTBTV1UFzKXVSYNK4zjPiPyEVq7ZIDedMahbCRIh3s6pir8KAmmYBUVrKKSyq_iAG0uB3xbcINcLfoOrG0pBqTeoaFpxyr6CFW4irIqz4HSKM9capKKZ5YL6qx0ouADtAG2qhYnZJeuSW1nPklMgRhwgF4GCSD2qAE5NNZns5naOzrsCb2OQlXjv8_qeBDDawm4wHqS6z1J73lsr3uj2zQKugCuV5fN2UwxHsrldIAeL7bQL_34jF4KWQwQ722unmb6PfXka6A9zzhwD3ktbHVbTEV_O7tK7U__QXYD3dodHeyr_b3hp2fo9qJqyEiarqPVeXtWPkc37Pl8MmtfBI_zE3o9fl0 |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagoIoL78dCoRZCoj2YJnFix8fyKFS0q4ouVW-WH8my0japkm1F_zS_AY_jLKTQA-Jqj-3EHo_Hms_fIPRKx3mklDWEJUaQ1DkYxHnVgrDC8tQtONUe5Xu0x8fj_PhYHARsTtuj3fuQZPemAViaqsXWqS27LZ6zrdiZVIgLcCKIG-w6upFCxiC4rB8eLYMIPI_ywObzl0aDg8jz9f9plX87li5DJi_FTf1xtHPnP3_kLrod_FC83SnOPXStqO6j1f0QaX-Afkz8iuATAOxh1TTqAqtAYILrEk8VvP-tIdknHpPp_MIp1MUcf9ynuPgewLWVa2ExIETcSAs4FK1TpMaXwnuKc7jwQ2e-rjdfeONwsj3ZJLSXgbJZhZsA28OLGjtjaX2OBgyBB1dbzuaB_9f37r_6HGjR5yALuBPooqor0p4o18I3mztDhw2offMQfd35MHn3iYTcEMQwwRbEWqY5U2lkVFZQm3OaFblOaZLbONZFQXURmzQqy0gzobWxEF-NFdMZFVSkjD5CK27Q4gnCeREzyOBFVSZSUSZCs0xb7jwld3IrG43Qm15RpAnE6ZC_Yy79BSpnElZRwipKId0qjtDGssFpxxlytehb0LylGJB9-4K6mcpgO2RmS8rKNAWqozSxsY5KnhieU2uEzTM-Quugt7J7Obs0WXI7cc5jDISBI_TSSwDhRwWIoqk6a1u5e_hlIPQ6CJW1-z-jwgMNN0vAETaQXBtIOotkBtXr_QaSUAUwvqqoz1rJuA-j0xF63G2nX_PjPH2Ri2yE-GCjDWZmWFPNvnk69IQDJ5Gbhc1-u8lgh9urpv3pP8iuo9WD9ztyb3f8-Rm61QUTGYnjNbSyaM6K5-imOV_M2uaFNz4_AbNYh0E |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Tissue+micro+array+analysis+of+ganglioside+N-glycolyl+GM3+expression+and+signal+transducer+and+activator+of+transcription+%28STAT%29-3+activation+in+relation+to+dendritic+cell+infiltration+and+microvessel+density+in+non-small+cell+lung+cancer&rft.jtitle=BMC+cancer&rft.au=van+Cruijsen%2C+Hester&rft.au=Ruiz%2C+Mari%C3%ABlle+Gallegos&rft.au=van+der+Valk%2C+Paul&rft.au=de+Gruijl%2C+Tanja+D&rft.date=2009-06-11&rft.pub=BioMed+Central&rft.eissn=1471-2407&rft.volume=9&rft.spage=180&rft.epage=180&rft_id=info:doi/10.1186%2F1471-2407-9-180&rft_id=info%3Apmid%2F19519895&rft.externalDocID=PMC2705377 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2407&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2407&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2407&client=summon |